IMMUNOGENE ZUSAMMENSETZUNG

European patent · EP3513806 · In force

Register entry

Publication number
EP3513806
Application number
EP19159001
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Dec 3, 2013
Published
Jul 24, 2019
Granted
Jan 25, 2023
Protection ends at the latest
Dec 2, 2033
Next annual fee due
Dec 31, 2026
IPC classes
A61K 39/08 (2006.01)
C07K 14/33 (2006.01)
Priority
GB 201221875 05.12.2012
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jan 1, 2026

    Change

    Published in Swissreg on 01.01.2026

  2. Jan 1, 2025

    Change

    Published in Swissreg on 01.01.2025

  3. Jan 1, 2024

    Change

    Published in Swissreg on 01.01.2024

  4. Dec 6, 2023

    Change

    Published in Swissreg on 06.12.2023

  5. Feb 24, 2023

    Agent entered

    Representative
    AWA Switzerland Ltd., Case Postale 2243, 2800 Delémont 2

    Published in Swissreg on 24.02.2023

  6. Jan 25, 2023

    Granted

    Published in Swissreg on 25.01.2023

Parties

Holder

GlaxoSmithKline Biologicals SA

Rue de l'Institut, 89, 1330 Rixensart, BE

Agent

AWA Switzerland SA

AWA Switzerland Ltd.

Case Postale 2243, 2800 Delémont 2

Inventor

BOUTRIAU, Dominique

1330 Rixensart, BE

WALLEMACQ, Hugues

1330 Rixensart, BE

GERMAIN, Sophie Marie Jeanne Valentine

1330 Rixensart, BE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.